The remedy can slow the course of the disease by up to 35 percent, but NICE does not see good value for money
Alzheimer's drug blocked in UK due to cost debate
- Center-left1
- Center-right1
1 agency rewrite / co-publication detected
Summary
The difference between caring for a person with mild cognitive impairment and severe Alzheimer’s disease was set at just 0.04 – suggesting a 4 percent decline in quality of life. Home World Status: 17.07.2026, 11:58 PM Comments Follow us on Google A new Alzheimer's drug could slow the disease by 35 percent - But in the UK, a cost debate prevents access for patients. Britain became the first country in Europe to approve the drugs lecanemab and donanemab in 2024, after studies found that they slow down degradation in early Alzheimer’s disease by up to 35 percent.
Furthermore, In the UK, a cost debate is preventing many people from accessing new Alzheimer's drugs. © picture alliance/Jens Kalaene However, hopes for rapid adoption in the NHS were immediately dashed when NICE 2025 concluded that the treatments did not offer good value for money. In Germany, the drugs are available since autumn 2025. A spokesperson said: “Our goal is to ensure that suitable people with Alzheimer’s disease can gain access to approved therapies in the NHS.” When approving the Alzheimer's drugs, UK regulators concluded that they slow disease progress by 27 to 35 percent in people with early Alzheimer's disease.
In addition, However, these adjustments are counteracted by other changes in the model’s assumptions, including lowering the average number of unpaid carers per patient from 1.8 to one. Letters sent out by NICE on Wednesday said both manufacturers would now “check whether they want to enter into commercial talks with NHS England.”.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
The difference between caring for a person with mild cognitive impairment and severe Alzheimer’s disease was set at just 0.04 – suggesting a 4 percent decline in quality of life.
reliability low1/2 sourcesHome World Status: 17.07.2026, 11:58 PM Comments Follow us on Google A new Alzheimer's drug could slow the disease by 35 percent - But in the UK, a cost debate prevents access for patients.
reliability low1/2 sourcesBritain became the first country in Europe to approve the drugs lecanemab and donanemab in 2024, after studies found that they slow down degradation in early Alzheimer’s disease by up to 35 percent.
reliability low1/2 sourcesIn the UK, a cost debate is preventing many people from accessing new Alzheimer's drugs. © picture alliance/Jens Kalaene However, hopes for rapid adoption in the NHS were immediately dashed when NICE 2025 concluded that the treatments did not offer good value for money.
reliability low1/2 sourcesIn Germany, the drugs are available since autumn 2025.
reliability low1/2 sourcesA spokesperson said: “Our goal is to ensure that suitable people with Alzheimer’s disease can gain access to approved therapies in the NHS.” When approving the Alzheimer's drugs, UK regulators concluded that they slow disease progress by 27 to 35 percent in people with early Alzheimer's disease.
reliability low1/2 sourcesHowever, these adjustments are counteracted by other changes in the model’s assumptions, including lowering the average number of unpaid carers per patient from 1.8 to one.
reliability low1/2 sourcesLetters sent out by NICE on Wednesday said both manufacturers would now “check whether they want to enter into commercial talks with NHS England.”.
reliability low1/2 sources
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Center-left1
Center-right1
